Alnylam Pharmaceuticals Stock Price. Everything You Need To Know About The Alnylam Pharmaceuticals Stock!
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that focuses on developing therapeutics based on ribonucleic acid interference (RNAi). With five marketed products and over ten clinical programs in development, Alnylam is a major player in the biopharmaceutical industry. The company’s pipeline includes products that target genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.
Alnylam’s RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic that targets transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA) and to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic that targets hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.
Investors interested in Alnylam’s stock should keep an eye on the latest premarket updates and stocks share price today. As a leading biopharmaceutical company, Alnylam’s market cap reflects its strong position in the industry. With several late-stage clinical programs in development, Alnylam is well-positioned for future growth and success.
Alnylam Pharmaceuticals Stock Price. Everything You Need To Know About The Alnylam Pharmaceuticals Stock! performance
- Employees 2002
- Company HQ Cambridge
- Website https://www.alnylam.com/
- ALNY Asset Type Common Stock
- ALNY Market Capitalization 18.2B
- Earnings Per Share -3.52
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking for investment opportunities in the US stock market? Look no further than Alnylam Pharmaceuticals, a leading biopharmaceutical company revolutionizing the treatment of rare genetic diseases. With their innovative RNA interference (RNAi) therapeutics, Alnylam is at the forefront of medical advancements. But how can you invest in this promising stock from your home country? At Zorion, we make it easy for retail investors like yourself to access the US market. With our investment platform, you can invest in real US stocks, including Alnylam Pharmaceuticals, and even Pre-IPO companies, without any hassle. Furthermore, Zorion offers valuable investment insights and recommendations to help you make informed decisions. Our educational resources and materials are specifically designed to enhance your investment knowledge, ensuring you stay ahead of the game. Don’t miss out on the opportunity to invest in Alnylam Pharmaceuticals and be part of the future of healthcare. Join Zorion today and start your investment journey with us.
